Project Grant HT94252310968
Award Date
9/30/23
Completion Date
9/29/26
Dollars Obligated
$573K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Tacoma, WA 98402, USA
Similar Awards
The U.S. Department of Defense's Defense Health Agency awarded a $488,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Geneva Foundation, a non-profit organization. The grant, awarded on July 1, 2024, supports research to investigate novel mechanisms of regulating the PAX3-FOXO1 fusion oncogene in rhabdomyosarcoma, a type of soft tissue cancer. The research aims to advance treatments for this rare and aggressive form of cancer, with a projected...
This Project Grant award for $366,000.00, awarded on Sep 30, 2024 by the Defense Health Agency, supports research conducted by The Geneva Foundation to identify functional structural variants that influence therapy outcomes for human castration-resistant prostate cancer. The award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a broad range of biomedical research initiatives to improve health outcomes for military service members,...
The Defense Health Agency awarded a $1,117,352 Project Grant to Trustees of Boston University's Boston University Medical Campus to develop a novel and practical intervention for detoxification of per- and polyfluoroalkyl substances (PFAS) in humans. The grant, funded under the Military Medical Research and Development program (CFDA 12.420), supports the university's research to transform health care for Service Members and the public through innovative biomedical research. As part of the...
The Geneva Foundation was awarded a $1,597,740 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 2022 to June 2026 to develop new methods for accessing extracellular vesicle MDM2 DNA cargo as a potential liposarcoma biomarker. Through support of basic, applied, and advanced biomedical research, the Military Medical Research and Development program aims to transform...
This $701,121 federal Project Grant award from the Department of Defense's Defense Health Agency, issued under the Military Medical Research and Development program (CFDA 12.420), supports research on the ovarian-disrupting effects and mechanisms of per- and polyfluoroalkyl substances (PFAS). The project is being conducted by Rutgers, The State University of New Jersey's RBHS-School of Nursing over a 3-year period from September 2023 to September 2026. The research aims to develop a better...
The University of Illinois was awarded a $798,912 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant supports research to investigate how PFAS (per- and polyfluoroalkyl substances) exposures can reprogram prostate stem cells and drive carcinogenesis and cancer progression. The 3-year project, running from July 1, 2023 to June 30, 2026, will advance scientific understanding of how environmental PFAS exposures may...
The U.S. Defense Health Agency awarded a $325,650 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Geneva Foundation, a non-profit organization in Tacoma, WA. The grant, awarded on March 1, 2025, supports a 2-year research initiative to assess changes in the human blood proteome following total sleep deprivation. The Geneva Foundation, which specializes in biomedical research and medical technology development for federal agencies, will lead this...
The U.S. Department of the Army Medical Command awarded a $909,510 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Geneva Foundation, a non-profit organization based in Tacoma, Washington. The grant, awarded on May 1, 2025, supports "Precision Therapy for the Eradication of Brain Metastatic Breast Cancer" research, with a performance period ending on April 30, 2028. The Geneva Foundation, which holds a Multiple Award Schedule contract with...
The Department of Defense, through the Military Medical Research and Development program (CFDA 12.420), awarded a $1,857,470 Cooperative Agreement to The Geneva Foundation to develop a multiplex testing platform that can simultaneously detect and identify Plasmodium species infections. This platform will serve as both a diagnostic tool and an epidemiological surveillance tool. The project performance period is from June 1, 2024 to May 31, 2028. Under a $268,312 sub-award, Meso Scale...
The Geneva Foundation was awarded a $1,054,546 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will support research into the role of U2AF1 mutations in myelodysplastic syndrome and their potential role as a noncanonical splicing factor in bone marrow failure. Through July 2025, the Geneva Foundation will investigate how these genetic mutations impact splicing and the development of...